Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), a global pharmaceutical company incorporated in Ireland, filed this Current Report on November 4, 2020. The filing announces the release of earnings results for the third quarter ended September 26, 2020. The detailed financial data is contained in the attached press release (Exhibit 99.1), which is not included in the text of this 8-K.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release and defines the methodology for the non-GAAP financial measures presented in the accompanying press release.
The Company utilizes non-GAAP measures to evaluate ongoing operating trends, excluding items such as:
- Amortization expense related to acquired intangible assets.
- Impairment charges and restructuring costs.
- Acquisition and integration-related charges.
- Loss on early debt extinguishment.
- Unusual litigation and separation expenses.
Material Changes and Adjustments
The filing details specific adjustments made to derive non-GAAP results for the three and nine months ended September 26, 2020, compared to the prior year periods. Notable items affecting comparability include:
- Acquisitions: Adjustments for net sales from the 2019 Ranir acquisition and the 2020 Dr. Fresh (High Ridge Brands) acquisition.
- Divestitures: Exclusion of results from the divested animal health business, Canoderm prescription product, and Rosemont Pharmaceuticals business.
- Product Issues: Adjustments for the albuterol sulfate inhalation aerosol recall returns reserve and the prior year's Ranitidine market withdrawal.
- Other Items: Foreign currency translation movements, changes in financial assets, and gains/losses on investment securities.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, outlook figures, or management commentary beyond the rationale for using non-GAAP measures. Management states these measures are used for planning, forecasting, and determining compensation. The text notes that investors should consider non-GAAP measures in conjunction with, not in lieu of, GAAP financial statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, net income, and EPS figures.
- Verify the reconciliation between GAAP and non-GAAP results to understand the magnitude of excluded items like amortization and restructuring.
- Assess the impact of the albuterol recall and Ranitidine withdrawal on the RX base business growth.
- Confirm the organic growth rate excluding the impact of the Ranir and Dr. Fresh acquisitions.
- Check the Company's liquidity position and debt levels in the full quarterly report (10-Q) referenced by this filing.